


















Melanoma is a usually aggressive malignant neoplasm of 
neuroectodermal origin arising from activated and genetically al-
tered melanocytes.1,2	Although	cutaneous	melanomas	 (CM)	 repre-
sent	only	4-5%	of	the	skin	neoplasias,	they	have	great	clinical	and	
epidemiological relevance for being responsible for up to 80% of the 
deaths	caused	by	skin	cancer.3,4
The	recognition	of	risk	factors	for	CM	development	is	im-
portant from both clinical and public health perspectives.5 Multi-
ple	 risk	 factors	have	been	associated	with	CM	development	 such	




er	 risk	 factors	 include	 freckles	 later	 in	 life,	 smoking,	obesity,	Par-
kinson’s	 disease,	 immunosuppression,	 and	 home	 or	 professional	
use	of	pesticide.	However,	more	studies	are	needed	to	evaluate	the	
strength of these associations.7-13
Incidence rates of CM have increased globally.3,14	 In	Aus-
tralia,	the	country	with	the	highest	CM	incidence	rates,	this	is	the	
fourth most prevalent tumor responsible for 10.2% of all new cancer 
cases.	In	2015,	12,960	new	cases	of	CM	were	expected,	with	an	esti-
mated	incidence	of	49	cases	per	100,000	population.	Its	age-adjusted	
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limb with Breslow depth S I. The comparison of the characteristics of cutaneous melanoma in the elderly and non-elderly (< 
60	years	old)	showed	significant	differences	with	respect	to	all	the	variables	studied.	
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incidence	increased	from	27	cases	per	100,000	population	in	1982	to	
48 cases in 2011.15
In	the	United	States,	CM	is	the	sixth	most	frequent	tumor.16 
In	 2014,	 approximately	 76,100	 individuals	 were	 diagnosed	 with	
CM.17	 Between	2008	 and	2012,	 the	 incidence	of	CM	 in	Americans	
was	estimated	at	21.6	per	100,000	population	per	year.16 The average 
risk	of	developing	CM	during	lifetime	in	the	US	increased	from	1	for	
every	1,500	people	in	1935	to	1	for	every	30	in	2009.18
In	 Europe,	 in	 2012,	 the	 age-standardized	 rates	 of	 CM	 for	
both	 sexes	 among	 the	 European	 population	was	 11.1	 per	 100,000	
population.	Switzerland	ranks	first	with	a	rate	of	25.8	per	100,000	












in	 2005	was	 7.8	 cases	per	 100,000	population.23 Founded and col-





of CM according to demographic and histological characteristics 
are scarce.25 Deficiency	of	 compulsory	notification,	 lack	of	 reliable	
central	registration,	and	lack	of	priority	by	public	health	managers	
are pointed out as the main barriers to a better understanding of the 
problem and the implementation of control actions.25
Therefore,	the	present	study	intends	to	describe	the	profile	






ary 2003 and December 2014 in the resident population of Joinville.
We collected the reports of all cases of primary CM diag-
nosed	in	the	only	three	laboratories	of	Pathological	Anatomy	of	the	
city,	which	are	responsible	for	the	diagnosis	of	patients	residing	in	
Joinville and surrounding cities. In order to identify and select the 












We used full	names	and	dates	of	birth	 to	 confirm	 the	ad-
dress	 of	 the	 subjects	 and	 to	 identify	 the	 existence	 of	multiple	 re-
ports of the same case (what eventually occurs when the diagnosis 
is the product of incisional biopsy followed by excision or margin 
enlargement).	 In	 the	cases	of	patients	with	 reports	of	CMs	result-
ing	 from	 incisional	 biopsy	 and	 subsequent	 complete	 excision,	we	
considered	the	report	with	the	highest	Breslow	thickness	measure.	
There was no access or consultation of medical records or patients. 
We	reviewed	no	histological	specimens,	accepting	the	diagnosis	and	
the descriptions as described in the reports.
Inclusion criteria were: to be a resident of Joinville and to 





residual neoplasia or enlargement of the surgical margin.
After	 applying	 the	 inclusion	 and	 exclusion	 criteria	 to	 the	





for	 other	 reasons	 (such	 as	 inconclusive	 reports,	 other	 neoplasms,	
and	neoplasms	affecting	a	different	organ,	2.3%).
Based	on	these	procedures,	we	believe	that	all	cases	of	CM	
affecting	 individuals	 living	 in	 Joinville	were	 included,	 qualifying	
our study as a population-based survey.
The data were entered in the Excel 2011 spreadsheet and then 








The individuals were grouped in 2 age-classes: young (less 
than	60	years)	and	elderly	(60	years	and	over),	as	defined	by	the	WHO.
The gross rate of CM incidence for Joinville was calculated for 
each year using the following formula: number of new cases of CM 
each year divided by the population of the same year (estimated by the 
Brazilian	Institute	of	Geography	and	Statistics	–	IBGE	–	and	published	
on	Datasus	system)	multiplied	by	100	thousand	population.26-29
In order to allow comparisons between locations with dif-
ferent	age	groups	and	time	series	analysis,	we	standardized	the	co-
efficients	by	adjusting	the	gross	rate	of	CM	incidence	to	the	world	
standard	population	 (2010)	and	 to	 the	Brazilian	 standard	popula-
tion	(2010	census)	by	age	group	and	gender.30-34
This	work	was	approved	by	the	Ethics	Committee	of	the	Uni-
versidade da Região de Joinville (UNIVILLE)	–	Joinville	(SC),	Brazil.
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RESULTS
We	identified	819	CM	patients	in	the	study	period,	of	which	
461	were	women	(56.3%)	and	358	were	men	(43.7%).	Table 1 shows 
the	coefficients	of	incidence	of	primary	CM	in	residents	of	Joinville	
from 2003 to 2014.
In	Joinville,	the	comparison	of	the	age-adjusted	coefficient	









drennium was 44.0% among men and 51.2% among women.
Figure	 1	 shows	 the	 gender-stratified	 coefficients	 of	 inci-
dence of Joinville over time.
Of	the	893	CM	cases	identified,	the	most	frequent	locations	
were	 the	 trunk	 and	 the	 upper	 limb,	with	 a	 predominance	 of	 the	
superficial	 spreading	melanoma	 (SSM)	 histological	 type,	 Breslow	
stage	1,	and	Clark	levels	III	and	IV.	The	mean	age	was	54.6	years,	
with a standard deviation of 16.5 years.
Comparison of CM characteristics among elderly (60 years 
of	 age	 or	 older)	 and	non-elderly	patients	 (under	 60	 years	 of	 age)	
showed	 significant	 differences	 in	 relation	 to	 all	 variables	 studied	
(Table	 2).	 CMs	 located	 on	 the	 trunk	 and	 upper	 limb	 were	 more	
frequent	 in	young	patients	while	 lesions	 located	on	 the	head	and	
neck	were	more	frequent	in	the	elderly	(p	<	0.001).	Regarding	his-
tological	 type,	 there	was	a	predominance	of	SSM	among	younger	
patients	 and	nodular	melanoma	 (NM)	and	 lentigo	maligna	mela-
noma	(LMM)	among	the	elderly	(p	<	0.001).	As	for	Breslow	depth,	
S1 was predominant in the group of young people and S3 and S4 
in	the	elderly	(p	<	0.001).	Likewise,	Clark	level	III	prevailed	in	the	
younger	group,	and	Clark	IV	and	V	in	the	elderly	(p	<	0.001).	Most	
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Table 1: Distribution of the new cases of CM according to the population of Joinville, gross rate of CM incidence, gender-adjusted 
rates, and rates adapted to the Brazilian and world standard based population each year











  Male 
CIWP
2003 39 		461,578   8.5   12.5   12.8   8.2   12.3   12.5   8.7   12.6   13.1
2004 58 		469,362   12.3   17.4   17.3   16.1   21.6   21.7   8.6   13   13
2005 40 		487,047   8.2   10.5   10.5   8.2   9.9   9.8   8.3   11   11.1
2006 46 		496,050   9.3   12.5   12.5   9.2   13.3   13.5   9.3   11.7   11.6
2007 70 		504,983   13.8   15.5   15.4   18   20.1   20.1   9.6   10.7   10.8
2008 81 		492,101   16.5   18.9   19.1   16.5   17.9   18   16.5   19.9   20.1
2009 109 		497,329   21.8   23.9   24   27.8   29.5   29.4   15.9   18.1   18.6
2010 105 		515,288   20.4   20.9   20.8   21.2   21.1   20.8   19.6   20.8   20.7
2011 77 		520,905   14.8   15.2   15.2   17.9   17.5   17.2   11.6   12.8   13.2
2012 93 		526,338   17.7   18.5   18.5   19.6   19.8   19.7   15.7   17.1   17.3
2013 87 		546,981   15.9   16.8   16.7   20.7   21.3   21.1   11   12.1   12.3






















son between each histological category showed a predominance NM 
and	SSM	in	men	(p	=	0.026	and	p	=	0.0335,	respectively).
The comparison of MC characteristics varied according to 





and	 neck;	 acral lentiginous melanoma	 (ALM)	 on	 the	 lower	 limb;	
and	SSM	on	the	upper	limb	and	trunk	(p	<	0.001)	(Table	4).
Of	 the	 819	patients,	 53	 (6.5%)	 had	more	 than	 one	primary	
CM	(95%	CI,	4.9%-8.4%).	The	mean	time	between	the	lesions	was	2.22	
years	and	the	median	was	less	than	1	year	(0.92),	with	a	standard	de-
viation of 2.71 years. The minimum time was less than 1 year (with 10 
cases	of	synchronous	CMs)	and	the	maximum	time	was	10.05	years.	
The	absolute	majority	of	subjects	(74%)	had	up	to	2	primary	CMs,	fol-
lowed by 23% with 3 primary CMs. Cases of multiple CMs occurred 
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Table 2: Distribution of CM cases according to anatomical site and age group in Joinville, 2003-2014






CM characteristics n (%)   n (%)   n (%)  
Location       < 0.001
	 Head/neck 176	(19.7) 		65	(11.9) 111	(32.0)*  
 Lower limb 166	(18.6) 		102	(18.3) 		64	(18.4)  
 Upper limb 224	(25.1) 154	(28.2)* 70	(20.2)  
	 Skin,	WFS	 14	(1.6) 		9	(1.6) 		5	(1.4)  
	 Trunk 313	(35.1) 216	(39.6)* 97	(28.0)  
Type       < 0.001
 SSM 516	(57.9) 367	(67.3)* 149	(43.1)  
 NM 168	(18.9) 		73	(13.4) 95	(27.5)*  
 LMM 91	(10.2) 		37	(6.8) 54	(15.6)*  
	 ALM 10	(1.1) 		4	(0.7) 		1	(0.3)  
	 NVM 9	(1.0) 		7	(1.3) 		2	(0.6)  
 DM 5	(0.6) 		4	(0.7) 		1	(0.3)  
 BNM 1	(0.1) 		0	(0.0) 		1	(0.3)  
	 Melanoma,	WFS 89	(10.0) 		50	(9.2) 		39	(11.3)  
 Others: SM 3	(0.3) 		3	(0.6) 		0	(0.0)  
	 Others:	ATM 1	(0.1) 		0	(0.0) 		1	(0.3)  
Breslow (n=859)       < 0.001
 In situ 203	(23.6) 		125	(23.7) 		78	(23.5)  
 S I 369	(43.0) 254	(48.2)* 115	(34.6)  
 S II 112	(13.0) 		72	(13.7) 		40	(12.0)  
 S III 81	(9.4) 		37	(7.0) 44	(13.3)*  
	 S	IV 94	(10.9) 		39	(7.4) 55	(16,6)*  
Clark (n=864)       < 0.001
 I 203	(23.5) 		125	(23.7) 		78	(23.1)  
 II 173	(20.0) 		107	(20.3) 		66	(19.6)  
 III 232	(26.9) 167	(31.7)* 65	(19.3)  
	 IV 216	(25.0) 		114	(21.6) 102	(30.3)*  
	 V 40	(4.6) 		14	(2.7) 26	(7.7)*  
 Multiple CMs 127	(14.2) 		61	(11.2) 		66	(19.0) 0.002
Notes: ALM =	acral	lentiginous	melanoma;	ATM =	equine-/animal-type	melanoma;	BNM = melanoma	from	blue	nevus;	CM =	cutaneous	melanoma; DM = desmoplastic	melanoma;	






ry CM with analysis of clinical and histological data in the city of 







ational activities with intermittent sun exposure.
Currently,	despite	the	existence	of	a	pioneering	state	com-
pulsory	 cancer	 notification	 system	 (Sistema Estadual de Registro de 
Câncer no Estado de Santa Catarina	 –	 SISCAN),	 its	 database	 is	 un-
fortunately	 incomplete	 due	 to	 underreporting	 of	CM	 cases,	mak-
ing it impossible to conduct an actual population-based study.35,36 
However,	 the	methodological	 procedures	 adopted	 in	 the	 present	




In	2003,	CIWP	of	 residents	of	 Joinville	was	12.8	 cases	per	









The	highest	 incidence	 rates	 of	CM	are	 found	 in	Australia	
and	New	Zealand	 (40-60	 cases	 per	 100,000	population).10,37 In the 
USA,	between	2008	and	2012,	the	number	of	new	cases	of	CM	was	
28.2	 in	men	and	16.8	 in	women	per	 100,000	population.16 The in-











Bonilla et al.	 (2007)	 published	 the	 incidence	 of	 neoplasias	
in	the	city	of	Joinville	in	2005,	and	the	gross	rate	of	CM	incidence	
was	7.8	per	100,000	population,	close	to	the	gross	rate	found	in	the	
present study in the same year.2,8 The small variation between the 
two	studies	is	due	to	methodological	differences,	since	the	work	of	
Bonilla et al. did not have access to data from one of the three labo-
ratories	in	the	municipality,	which,	at	the	time,	was	responsible	for	
10.6% of the biopsies performed in Joinville.23
The	Brazilian	phenotypic	distribution	shows	great	hetero-
geneity throughout the latitudes. In the states of Santa Catarina 
and	Rio	Grande	do	Sul,	89%	of	 the	population	 in	 the	urban	areas	
have	fair	skin.40	Although	our	work	did	not	assess	the	skin	color	of	
Epidemiological and histopathological aspects of primary cutaneous melanoma in residents of Joinville, 2003-2014 49
An Bras Dermatol. 2018;93(1):45-53.
Table 3: CM distribution according to gender in relation to 
location, histological type, Breslow’s depth,  
and Clark’s level (n = 893)
 Total   Gender P-value*
 (n=893) Female   Male
 (n=507)   (n=386)
CM characteristics n	(%) 		n	(%) 		n	(%)
Location        < 0.0001
	 Head/neck 176	(19.7) 		84	(16.6) 92	(23.8)*  
 Lower limb 166	(18.6) 127	(25.0)* 39	(10.1)  
 Upper limb 224	(25.1) 		127	(25.0) 		97	(25.1)  
	 Skin,	WFS 14	(1.6) 		9	(1.8) 		5	(1.3)  
	 Trunk 313	(35.1) 		160	(31.6) 153	(39.6)*  
Type        0.341
 SSM 516	(57.8) 		309	(60.9) 		207	(53.9)  
 NM 168	(18.8) 		82	(16.2) 		86	(22.4)  
 LMM 91	(10.2) 		53	(10.5) 		38	(9.9)  
	 ALM 10	(1.1) 		6	(1.2) 		4	(1.0)  
	 NVM 9	(1.0) 		4	(0.8) 		5	(1.3)  
 DM 5	(0.6) 		3	(0.6) 		2	(0.5)  
 BNM 1	(0.1) 		0	(0.0) 		1	(0.3)  
	 Melanoma,	WFS 89	(10.0) 		48	(9.5) 		41	(10.7)  
 Others: SM 3	(0.3) 		2	(0.4) 		1	(0.3)  
	 Others:	ATM 1	(0.1) 		0	(0.0) 		1	(0.3)  
Breslow (n=859)        0.069
 In situ 203	(23.6) 		117	(23.8) 		86	(23.4)  
 S I 369	(43.0) 		223	(45.3) 		146	(39.8)  
 S II 112	(13.0) 		65	(13.2) 		47	(12.8)  
 S III 81	(9.4) 		46	(9.3) 		35	(9.5)  
	 S	IV 94	(10.9) 		41	(8.3) 		53	(14.4)  
Clark (n=864)        0.663
 I 203	(23.5) 		117	(23.5) 		86	(23.4)  
 II 173	(20.0) 		99	(19.9) 		74	(20.2)  
 III 232	(26.9) 		142	(28.6) 		90	(24.5)  
	 IV 216	(25.0) 		117	(23.5) 		99	(27.0)  
	 V 40	(4.6) 		22	(4.4) 		18	(4.9)  
 Multiple CMs 127	(14.2) 		76	(15.0) 		51	(13.2) 0.511
Notes: ALM = acral	lentiginous	melanoma;	ATM =	equine-/animal-type	melanoma;	BNM 
=	melanoma	from	blue	nevus;	CM =	cutaneous	melanoma;	DM = desmoplastic	melanoma;	
LMM =	lentigo	maligna	melanoma;	NM =	nodular	melanoma;	NVM =	nevoid	melanoma; 
SSM = superficial	spreading	melanoma; SM = spitzoid	melanoma;	and	WFS = without 
further	specifications	
Table 4: CM Distribution according to location, Clark’s level, Breslow’s depth, and histological type
CM characteristics   Location P-value
Head/neck   Lower limb   Upper limb 		Skin,	WFS 		Trunk
n	(%) 		n	(%) 		n	(%) 		n	(%) 		n	(%)
Clark’s level              < 0.001
 I 52	(31.1)* 26	(16.1) 		48	(22.2) 		4	(30.8) 		73	(23.8)  
 II 35	(21.0) 		26	(16.1) 		50	(23.1) 		1	(7.7) 		61	(19.9)  
 III 30	(18.0) 		44	(27.3) 		66	(30.6) 		3	(23.1) 		89	(29.0)  
	 IV 36	(21.6) 50	(31.1)* 50	(23.1) 		4	(30.8) 		76	(24.8)  
	 V 14	(8.4)*   15 2	(0.9) 		1	(7.7) 		8	(2.6)  
Breslow’s depth              0.004
 In situ 52 26	(16.5) 		48	(21.9) 		4	(30.8) 		73	(23.9)  
 S I 55	(33.7) 		65	(41.1) 110	(50.2)* 3	(23.1) 		136	(44.4)  
 S II 19	(11.7) 		25	(15.8) 		24	(11.0) 		1	(7.7) 		43	(14.1)  
 S III 14	(8.6) 24	(15.2)* 22	(10.0) 		2	(15.4) 		19	(6.2)  
	 S	IV 23	(14.1) 		18	(11.8) 		15	(6.8) 		3	(23.1) 		35	(11.4)  
Histological type              < 0.001
 LMM 41	(23.3)* 12	(7.2) 		18	(8.0) 		0	(0) 		20	(6.4)  
	 ALM 0 8	(4.8)* 2	(0.9) 		0	(0) 		0	(0)  
 NM 40	(22.7) 		37	(22.3) 		38	(17.0) 		5	(35.7) 		48	(15.3)  
 SSM 68	(38.6) 		87	(52.4) 151	(67.4)* 7	(50.0) 203	(64.9)*  
 WFS 21	(11.9) 		17	(10.2) 		14	(6.3) 		2	(14.3) 		35	(11.2)  
 Others 6	(3.4) 		5	(3.0) 		1	(0.5) 		0	(0) 		7	(2.2)  
Notes: LMM = lentigo	maligna	melanoma;	ALM	=	acral	lentiginous	melanoma;	NM	=	nodular	melanoma;	SSM	=	superficial	spreading	melanoma;	and	WFS	=	without	further	specifications	
the	individuals,	we	believe	that	the	observed	high	rates	are	partly	










graphic	 region	with	high	UVR	 levels.41	A	population-based	 study	





























in the elderly in Latvia and France.4,38
We observed a predominance of NM and LMM cancer types 
in	 the	 elderly,	with	 thicker	CMs.	Also,	 this	 group	presented	with	
the	 highest	 number	 of	 primary	 CMs.	 Similarly,	 in	 a	 rural	 region	
in	northern	France	 (Champagne-Ardenne),	 the	elderly	group	was	
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characterized	by	a	more	 advanced	 stage	at	 the	 time	of	diagnosis,	




















Among	women,	we	 observed	 a	predominance of CM af-
fecting	the	lower	limb	and,	in	the	men,	the	head/neck	or	the	trunk	
were	more	commonly	affected	(p	<	0.0001).	This	gender	difference	
revealed by our study is in agreement with the literature.2,4,6,38,42 In 
Londrina	 (state	of	Paraná)	and	 in	 the	 state	of	Rio	Grande	do	Sul,	
studies	 have	 identified	 the	 same	 tumor	 locations.2,45 Criado et al. 
(1999)	observed	a	2.3-fold	higher	risk	for	men	to	develop	CM	in	the	
posterior	trunk	region,	while	the	probability	of	lower	limb	involve-
ment was 2.4 times higher in females.2 This classical difference be-




owed),	 low	 level	 of	 schooling,	 obesity,	 autodetection	 or	 detection	
by	general	practitioner,	and	CM	of	the	head-neck	and	lower	limbs.9
SSM was the most prevalent type	 in	 our	 study	 (58%),	 in	
agreement	with	the	findings	of	a	German	study,	in	which	the	lesion	






of CM cases diagnosed during the study period in Joinville. These 
histological	types	comprise	the	group	of	thick	CMs	due	to	a	more	
aggressive	behavior	or	late	recognition,	since	they	are	often	amela-
notic or have atypical clinical appearance. These forms of CM are 
particularly	prone	not	to	be	recognized	by	classical	criteria,	such	as	
the	ABCD	rule.	Campaigns	aimed	at	improving	early	diagnosis	and	
reducing mortality should target particularly those more serious 
types of CM.38
When comparing CMs diagnosed in the 21st century with CMs 
diagnosed	 between	 1972	 and	 1982,	 it	 is	 possible	 to	 notice	 improve-
ments	in	the	early	detection	of	SSM,	but	not	of	NM.	SSM	is	typically	
diagnosed when it is still thin and has lower rates of ulceration as op-
posed to NM. Previous data have established that NM is often detected 
with	2mm	or	more.	A	study	on	cancer	registry	 in	Queensland,	Aus-
tralia	(2009),	identified	the	profile	of	individuals	at	the	highest	risk	of	
developing	 thick	NMs:	men,	older	 individuals,	and	 those	who	have	
not been examined by a physician in the last three years.10
CM	survivors	are	at	a	higher	risk	of	developing	other	sub-




tients with a history of CM.  These patients should be well informed 
about	the	risk	of	subsequent	skin	cancer	development	and	the	need	
for sun protection.14	 In	 the	study	period,	6.5%	of	 the	subjects	had	
more	than	one	primary	CM.	The	frequency	we	found	for	individ-
uals	with	multiple	CMs	is	in	accordance	with	the	literature,	which	
reports incidence rates between 0.5 and 8.6%.4,46
We observed that the mean time between CMs was approx-
imately	2	years.	In	a	study	conducted	in	Latvia,	the	following	pri-
mary	CM	appeared	during	the	first	year	after	the	initial	diagnosis	
in 29-59% of cases.4
The	majority	 of	 recidivist	 subjects	 (74%)	were	 affected	by	
up	 to	 2	primary	CMs.	 In	 individuals	with	multiple	CMs,	 it	 is	 in-





cation of physical examinations during clinical follow-up.14
Savoia et al.	 (2012),	 in	 a	 single-institution	 database	 with	
4,938	patients	diagnosed	with	CM,	observed	the	characteristics	of	
270 patients who had 639 multiple primary CMs over 34 years. Most 
of	 them	(76.7%)	developed	only	one	new	lesion.	The	authors	also	
observed	a	significantly	lower	mean	Breslow	thickness	in	the	new	
lesion	 (p	<	0.001)	and	a	 smaller	number	of	NM.	 Interestingly,	 the	
prognosis of those who had multiple CMs was better than in those 
with a single lesion.46
The	increased	risk	of	developing	CM,	BCC,	or	SCC	after	the	
first	CM	suggests	a	partially	common	etiology	of	RUV-induced	field	




as	a	 common	risk	 factor,	whereas	SCC	development	 is	 associated	
with	cumulative	exposure	to	UVR.	More	likely,	the	increased	risk	of	
developing	a	SCC	after	a	CM	may	be	driven	by	the	LMM	subtype,	
which affects more often the face and is also associated with chronic 
and	elevated	levels	of	UVR	exposure.14
Patients with CM need to be informed about their future 
persistent	 risk,	 should	 be	motivated	 to	 perform	 self-examination	
and,	 if	 possible,	 should	 have	 their	 entire	 body	 skin	 examined	 by	
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tool to cope with this disease. Planned primary and secondary pre-
vention actions are considered the cornerstone to reduce the burden 
of CM.47	Considering	that	the	incidence	of	CM	continues	to	increase,	
the	significant	burden	related	to	its	morbidity	and	mortality,	and	the	
considerable	 economic	 costs,	 timely	 recognition,	 assessment,	 and	
management of CM should be a priority in public health actions.48 q
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